Rhythm Pharmaceuticals (RYTM) Equity Average: 2017-2025
Historic Equity Average for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $68.5 million.
- Rhythm Pharmaceuticals' Equity Average rose 170.80% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 170.80%. This contributed to the annual value of $95.7 million for FY2024, which is 55.88% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported Equity Average of $68.5 million as of Q3 2025, which was up 1,845.01% from $3.5 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' Equity Average peaked at $366.3 million during Q2 2021, and registered a low of $3.5 million during Q2 2025.
- Its 3-year average for Equity Average is $101.5 million, with a median of $68.5 million in 2025.
- Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Equity Average was 170.80% (2025), while the steepest drop was 93.03% (2025).
- Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Equity Average stood at $303.2 million in 2021, then declined by 10.05% to $272.7 million in 2022, then plummeted by 32.67% to $183.6 million in 2023, then plummeted by 91.03% to $16.5 million in 2024, then soared by 170.80% to $68.5 million in 2025.
- Its last three reported values are $68.5 million in Q3 2025, $3.5 million for Q2 2025, and $20.3 million during Q1 2025.